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 Maintaining the integrity of the complex 
interplay between parathyroid hormone 
(PTH), the vitamin D endocrine system, 
and the fibroblast growth factor 23 
(FGF23) / klotho axis ( Figure 1 ) is essential 
to prevent or slow the progression of renal 
and cardiovascular damage in chronic 
kidney disease – mineral and bone disor-
der (CKD-MBD). 1 – 4 
 For decades, calcitriol replacement to 
correct the progressive reductions in renal 
calcitriol synthesis targeted exclusively the 
abnormal calcium-phosphate – calcitriol –
 PTH axis that causes the development 
of CKD-MBD. 1 – 3 However, stimulation 
of intestinal calcium and phosphate 
absorption by calcitriol sets the limits for 
calcitriol replacement, because hyperphos-
phatemia accelerates the progression of 
hyperparathyroidism, renal osteodystro-
phy, vascular calcifi cation, 1 – 3 and calci fi -
cation-independent cardiovascular 
dys function. 4 
 In people with normal kidney function, 
the stimulation of FGF23 and klotho pro-
duction induced by high levels of calcitriol 
prevents hyperphosphatemia and age-
related disorders. 1 – 3 Increased FGF23 /
 klotho signals enhance phosphaturia, 
thereby protecting from phosphate reten-
tion aft er PTH-induced phosphaturia is 
reduced by calcitriol ’ s suppression of 
PTH. Increased FGF23 / klotho signals also 
suppress the PTH secretion induced by 
residual hyperphosphatemia, thereby 
attenuating secondary hyperparathy-
roidism with less phosphate and calcium 
resorption from bone. Furthermore, 
increased FGF23 / klotho signals also pro-
tect from excessive calcitriol by suppress-
ing Cyp27b1, the enzyme responsible for 
calcitriol synthesis, and inducing Cyp24a1, 3 
thereby synergizing with calcitriol strong 
control of its own circulating levels. 
 In CKD, however, progressive decreases 
in renal and parathyroid klotho, an indis-
pensable part of a dimeric FGF23 receptor, 
blunt the benefi ts of high FGF23 levels: 
phosphaturia enhancement and PTH sup-
pression. 1 – 5 Furthermore, reduced renal 
tubular function impairs the induction of 
Cyp24a1 by FGF23 to degrade any excess 
of exogenous calcitriol. 3 Th us, CKD is an 
environment with high serum FGF23 
levels and klotho defi ciency, similar to 
that present in the klotho-null mouse that 
causes hyperphosphatemia and rapid pro-
gression of age-related disorders including 
vascular calcifi cations. 5 However, there is 
a clinically relevant diff erence between 
CKD and deletion of klotho: serum 
calcitriol levels are low in CKD but very 
high in the klotho-null mice despite high 
FGF23, thus demonstrating that high 
FGF23 cannot suppress the excessive renal 
calcitriol production in the absence of 
klotho, but also that renal klotho levels in 
CKD may suffi  ce to allow FGF23 to sup-
press Cyp27b1 and to induce Cyp24a1. 
 In klotho-null mice, deletion of the 
 Cyp27b1 gene attenuates hyperphos-
phatemia and aging disorders. 1 – 5 Th ere-
fore, marked inhibition of renal Cyp27b1 
by FGF23 in CKD has been interpreted as 
a compensatory mechanism to prevent 
the adverse eff ects of excessive calcitriol, 
and as evidence that calcitriol replacement 
should be avoided. However, the progres-
sion of renal and cardiovascular damage 
in CKD is markedly attenuated in trans-
genic mice genetically modifi ed to consti-
tutively express klotho. 1 Th us, maintaining 
calcitriol-mediated induction of renal and 
parathyroid klotho in CKD may help 
recover the phosphaturic and PTH-sup-
pressive benefi ts of functional FGF23 /
 klotho signals. Undoubtedly, optimal 
calcitriol replacement in CKD patients 
with high FGF23 levels should safely 
maintain renal and parathyroid klotho 
content, but avoiding excessive serum 
calcitriol levels. 
 A recent prospective trial demonstrat-
ing that low serum 25-hydroxyvitamin D 
levels (  <  23  ng / ml) and high FGF23 levels 
(  >  49  pg / ml) are good predictors of CKD 
progression 6 supports the notion that the 
correction of 25-hydroxyvitamin D defi -
ciency in CKD could help to restore renal 
and parathyroid klotho expression by 
locally produced calcitriol, with minimal 
impact on circulating calcitriol. The 
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present work of Dai  et al. 7 (this issue) 
evaluating the impact of the induction of 
renal Cyp24a1 by FGF23 on the conver-
sion of 25-hydroxyvitamin D to 24,25-
dihydroxyvitamin D, the first step in 
25-hydroxyvitamin D degradation, is of 
high translational relevance to the safe 
maintenance of benefi cial FGF23 / klotho 
signals. 
 Intriguingly, in humans and in the 
 Col4a3   −  /  −   mouse model of CKD, multi-
ple linear regression analysis demonstrates 
that elevated serum FGF23 and PTH 
levels are associated with low rather than 
high serum 24,25-dihydroxyvitamin D, 
despite a tenfold elevation in renal 
Cyp24a1 steady-state mRNA levels. 
Importantly, high PTH, a recognized 
suppressor of renal Cyp24a1 activity, is 
not responsible for the low serum 24,
25-dihydroxyvitamin D. PTH suppresses 
24,25-dihydroxyvitamin D synthesis by 
inducing Cyp24a1 mRNA degradation, 
and the mutant mice had markedly 
increased Cyp24a1 mRNA levels. 7 
 Limited substrate (25-hydroxyvitamin 
D) availability to the enhanced renal 
Cyp24a1 could reduce 24,25-dihydroxy-
vitamin D production. However, the hepatic 
capacity to synthesize 25-hydroxyvitamin 
D was intact. Wild-type and mutant mice 
had similar mRNA levels of Cyp27a1 and 
Cyp2r1, the enzymes responsible for the 
conversion of cholecalciferol to 25-hydroxy-
vitamin D. Furthermore, deletion of the 
 Fgf23 gene in the  Col4a3   −  /  −   mice resulted 
in an almost undetectable renal Cyp24a1 
mRNA expression, thus supporting the idea 
that high serum FGF23 markedly induces 
25-hydroxyvitamin D and 1,25-dihydroxy-
vitamin D degradation. Indeed, induction 
of calcitriol catabolism by FGF23 may pre-
vail over the apparent enhanced capacity 
for calcitriol synthesis, as high serum 
FGF23 correlates directly with low circulat-
ing calcitriol despite the unexpected three-
fold induction (instead of inhibition) of 
renal Cyp27b1. 
 How can the induction by FGF23 of 
25-hydroxyvitamin D degradation by 
Cyp24a1 reduce rather than increase 
serum 24,25-dihydroxyvitamin D? Th ere 
is a precedent: Similar reductions in serum 
24,25-dihydroxyvitamin D occur in trans-
genic rats that constitutively overexpress 
renal Cyp24a1. 8 Importantly, low serum 
24,25-dihydroxyvitamin D was not the 
result of an accelerated degradation of 
25-hydroxyvitamin D. Instead, albumin-
uria impaired the uptake of the fi ltered 
25-hydroxyvitamin D bound to vitamin 
D-binding protein (DBP), thereby reduc-
ing 24,25-dihydroxyvitamin D synthesis 
by the enhanced Cyp24b1. 8 
 Th e  Col4a3   −  /  −   mouse is a proteinuric 
model of progressive CKD. Th erefore, a 
reduced renal uptake of 25-hydroxy-
vitamin D should suffi  ce to impair renal 
synthesis of 24,25-dihydroxyvitamin D 
and also of 1,25-dihydroxyvitamin D 
despite tenfold increased Cyp24a1 and 
threefold increased Cyp27b1 mRNA 
levels. 7 24,25-Dihydroxyvitamin D also 
circulates bound to DBP. Th us, urinary 
loss of 24,25-dihydroxyvitamin D may 
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 Figure 1  |  Distinct PTH – calcitriol – FGF23 / klotho interactions in health and chronic kidney disease . Top: Tight parathyroid hormone (PTH) –
 calcitriol (1,25D) – FGF23 / klotho ( Klotho  ) regulatory loops in health. Bottom: In chronic kidney disease (red arrows), a decrease in renal and parathyroid 
klotho impairs the phosphaturic (Pu) and PTH-suppressive actions of FGF23. The finding of low serum 24,25-dihydroxyvitamin D (24,25D) despite 
marked induction by FGF23 of Cyp24a1, 7 the enzyme that degrades 25-hydroxyvitamin D (25D) and 1,25D, questions the actual role of high FGF23 in 
the reductions in serum 25D and 1,25D. Defective uptake of 25D by the failing kidney may explain both the low serum levels of 25D, 24,25D, and 1,25D 
regardless of serum FGF23 and the defective induction of renal klotho by locally produced 1,25D. Similar mechanisms may contribute to resistance to 
FGF23 in the parathyroid gland. 
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add to its impaired synthesis to further 
reduce its serum levels. 
 Dissociation between mRNA levels and 
enzymatic activity of the protein could 
also contribute to the abnormal serum 
levels of the three main vitamin D meta-
bolites associated with high FGF23 in the 
 Col4a3   −  /  −   mice. Th is possibility cannot 
be ruled out, as the work of Dai  et al. 7 lacks 
direct measurements of the activities of 
hepatic Cyp27a1 and Cyp2r1, and of renal 
Cyp27b1 and Cyp24a1. Nevertheless, the 
results of Dai  et al. in human CKD sup-
port the fi ndings in the  Col4a3   −  /  −   mouse: 
Serum 24,25-dihydroxyvitamin D is lower 
in CKD patients than in people with nor-
mal kidney function; this is also corrobo-
rated by Bosworth  et al. , 9 and supported 
by the early work of Ishimura  et al. at a 
time when FGF23 could not yet be meas-
ured. 10 Th ese reports also demonstrate the 
high variability among CKD populations 
in the onset and progression of abnor-
malities in the complex interplay between 
the vitamin D endocrine system and the 
FGF23 / klotho axis. Specifi cally, the three 
studies 7,9,10 agree only with regard to a 
direct association between serum 25-
hydroxyvitamin D and 24,25-dihydroxy-
vitamin D levels — Cyp24a1 substrate and 
product, respectively — supporting the 
view that defective production contributes 
to the low serum 24,25-dihydroxyvitamin 
D levels. Also, whereas the larger cohort 
of Bosworth  et al. 9 did not corro borate the 
independent association between high 
FGF23 and low 24,25-dihydroxyvitamin 
D reported by Dai  et al. , 7 the study by 
Ishimura  et al. 10 did not fi nd the direct 
association between high PTH and low 
24,25-dihydroxyvitamin D that Dai  et al. 
and Bosworth  et al. found. Furthermore, 
the direct correlation between serum albu-
min and the levels of the three main circu-
lating vitamin D metabolites, as shown by 
Ishimura  et al. , further supports the view 
that impaired renal uptake of the fi ltered 
25-hydroxyvitamin D, and not high 
FGF23, contributes to reduction of the 
production and circulating levels of 24,25-
dihydroxyvitamin D and 1,25-dihydroxy-
vitamin D in CKD. Undoubtedly, the 
fi ndings of Dai  et al. 7 provide important 
insights into previously unrecog nized 
aspects of the complex interplay between 
the vitamin D endocrine system and the 
FGF23 / klotho axis that progressively dete-
riorate in the course of CKD. 
 In view of the accuracy of low 25-
hydroxy vitamin D and high FGF23 levels 
in predicting poor renal outcomes, 6 the 
implementation of better supplementation 
strategies with vitamin D should benefi t 
from a direct assessment of the contribu-
tion of high induction of renal and / or 
extrarenal Cyp24a1 by FGF23 to enhance 
the metabolic clearance rate of 25-hydroxy-
vitamin D. 
 Th e fi ndings of Dai  et al. 7 also suggest that 
the high variability in serum 25-hydroxyvi-
tamin D levels observed upon vitamin D 
supplementation with ergocalciferol, chole-
calciferol, or even 25-hydroxy vitamin D may 
be due to the fact that, in the course of CKD, 
both catabolism of 25-hydroxyvitamin D 
and its conversion to 1,25-dihydroxyvitamin 
D are highly infl uenced by a number of fac-
tors other than abnormal serum levels of 
FGF23, PTH, and calcitriol, including 
impaired tubular reabsorption of vitamin D 
metabo lites from the glomerular ultrafi ltrate, 
and the magnitude of renal resistance to 
FGF23, a key variable that is difficult to 
measure. FGF23 actions in the kidney 
require klotho. Renal klotho expression 
decreases with the decline in glomerular fi l-
tration rate and also decreases if calcitriol 
decrea ses; thus, in theory, the lower the renal 
calcitriol production, the worse is the 
response to high FGF23 concentrations. Th is 
also includes production and catabolism of 
vitamin D metabolites to prevent the aging 
disorders associated with excessive calcitriol. 
Clearly, key translational issues remain 
unsolved: (1) Does renal resistance to FGF23 
(due to klotho defi ciency) have the same 
impact on renal and extrarenal Cyp27b1 and 
Cyp24a1 activity? (2) To what extent is the 
reduced renal mass, the excess of circulating 
FGF23, or any combination of both respon-
sible for abnormal renal and extrarenal vita-
min D synthesis and catabolism? (3) Do 
renal synthesis and catabolism of vitamin D 
metabolites undergo parallel changes as renal 
function declines? 
 We do know at present that 24,25-dihy-
droxyvitamin D levels are not a reliable 
measure of renal catabolism of vitamin D 
metabolites. 7,9,10 Indeed, serum 24,25-
dihydroxyvitamin D levels were low 
not only in the study by Dai  et al. , 7 whose 
subjects were selected to have low serum 
25-hydroxyvitamin D, but, more signifi -
cantly, in the study by Bosworth  et al. , 9 
which also included patients supplemented 
with nutritional vitamin D, as well as 
patients receiving active vitamin D therapy, 
the most potent inducer of Cyp24a1 activ-
ity. However, the study by Bosworth  et al. 
is only a transversal analysis of the eff ects 
of nutritional and / or active vitamin D sup-
plementation on serum 24,25-dihydroxy-
vitamin D levels. Measurements of changes 
in 1,25-dihydroxyvitamin D / 24,25-
di hydroxyvitamin D and / or 25-hydroxy-
vitamin D / 24,25-dihydroxyvitamin D 
ratios in prospective, well-powered studies 
could better reflect their accuracy as 
biomarkers of the impact of FGF23 / klotho 
signals on vitamin D synthesis and catabo-
lism in the course of CKD. 
 In the midst of the overwhelming com-
plexity of the vitamin D – FGF23 / klotho 
axis, there is good news for nephrologists 
regarding the accuracy of measurements of 
vitamin D status in CKD patients with high 
serum FGF23. 24,25-dihydroxyvitamin D 
elicits a 100% cross-reactivity with 25-
hydroxyvitamin D in all commonly used 
assays to measure 25-hydroxyvitamin D 
levels. Th erefore, the fi ndings of low serum 
24,25-hydroxyvitamin D in spite of high 
FGF23 in CKD 7,9,10 demonstrate that there 
is  no gross overestimation of the vitamin 
D status in CKD patients attributable to 
increases in serum 24,25-dihydroxyvita-
min D by FGF23. 
 Another important contribution of the 
reports by Dai  et al. 7 and Bosworth  et al. 9 
is the demonstration of our persistent lack 
of knowledge in an area nephrologists 
cannot aff ord to neglect. Being aware of 
what we do not know is the fi rst step in 
our search for the truth. 
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 A new  ‘ tac ’ for childhood 
nephrotic syndrome 
 Brian  Becknell 1 ,  Larry A.  Greenbaum 2 and  William E.  Smoyer 1 , 3 
 Calcineurin inhibitors (CNIs) are frequent first-line agents in children 
with steroid-resistant nephrotic syndrome (SRNS). However, limited 
randomized controlled trial (RCT) data are available comparing CNIs 
with alternative therapies. Gulati and colleagues report their experience 
with tacrolimus versus cyclophosphamide in childhood SRNS. Their 
results establish clear superiority of tacrolimus over cyclophosphamide 
and give further proof that RCTs in childhood SRNS are both feasible 
and vital for improving the standard of care. 
 Kidney International (2012)  82, 1049 – 1051.  doi: 10.1038/ki.2012.272 
 Th e initial response to corticosteroids is the 
single best predictor of long-term prognosis 
in childhood nephrotic syndrome. Follow-
ing diagnosis of steroid-resistant nephrotic 
syndrome (SRNS), the risk of a histologic 
diagnosis of focal segmental glomerulo-
sclerosis (FSGS) and of the development of 
end-stage renal disease increases dramati-
cally, with FSGS causing more than 10 % of 
cases of end-stage renal disease in children. 1 
Pediatric nephrologists have prescribed a 
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variety of alternative therapies to improve 
this ominous outcome, but a paucity of 
randomized controlled trials (RCTs) has 
resulted in a lack of consensus regarding the 
optimal treatment of SRNS. 2 
 Calcineurin inhibitors (CNIs) are 
frequent first-line agents in children 
with SRNS. Cyclosporin A (CsA) is the 
oldest and best-studied CNI in nephrotic 
syndrome (NS). By complexing with cyclo-
philin, CsA inhibits the phosphatase 
activity of calcineurin and prevents T-cell 
activation. Tacrolimus (FK506) also acts via 
inhibition of calcineurin, but this occurs 
through its association with FK506-binding 
protein (FKBP) ( Figure 1 ). However, the 
mechanism of CNI action in NS is unclear. 
While the initial rationale for the use of 
CNIs in NS rested on their immunomodu-
latory properties, recent experimental 
evidence demonstrates that calcineurin is 
expressed by podocytes, and CNIs or podo-
cyte-specifi c inactivation of calcineurin 
stabilizes the podocyte actin cytoskeleton 
and reduces proteinuria in response to 
glomerular injury. 3 Unfortunately, pro-
longed use of CsA has been associated with 
interstitial fi brosis. Data are limited regard-
ing long-term outcomes and dose-related 
toxicity in children taking tacrolimus for 
NS. 4,5 In a retrospective single-center study, 
tacrolimus induced complete remission 
in 15 of 16 patients (94 % ) aft er a median 
of 120 days of therapy. 6 Higher trough 
levels and a duration of therapy longer than 
24 months were each associated with 
increased tubular atrophy and interstitial 
fibrosis, potentially attesting to risks of 
prolonged tacrolimus use similar to those 
encountered in patients on CsA. In addi-
tion, CsA and tacrolimus were recently 
compared in a single RCT, and found to 
be equally effi  cacious in childhood SRNS, 
with comparable nephrotoxic profi les. 5 
 Alkylating agents such as cyclophospha-
mide have also been used in NS, albeit 
more frequently in steroid-dependent 
or frequently relapsing NS than in SRNS. 
Th e mechanism of alkylating agents in NS 
is also unclear, but they are presumed 
to act via inhibition of immune cells. 
Dose-related toxicities of cyclophospha-
mide include bone marrow suppression, 
alopecia, hemorrhagic cystitis, severe 
bacterial infections, malignancies, and 
gonadal toxicity. Intravenous pulse cyclo-
phosphamide has been prescribed to 
patients with steroid-resistant FSGS and 
promoted remission in certain cases, parti-
cularly children with secondary steroid 
resistance. 7,8 A single RCT comparing 
alkylating agents and CNIs found that 
intravenous cyclophosphamide was infe-
rior to CsA in inducing a partial remission 
in pediatric SRNS. 9 
 Gulati and colleagues 10 (this issue) now 
present their fi ndings from the fi rst pro-
spective, randomized, multicenter trial of 
intravenous cyclophosphamide versus 
tacrolimus in 131 children with SRNS. 
Consecutive patients aged 2 – 16 years with 
biopsy-confi rmed minimal-change NS 
(MCNS), FSGS, or mesangioproliferative 
glomerulonephritis were stratifi ed by early 
and late steroid resistance and randomized 
to 12 months of tacrolimus or 6 monthly 
infusions of cyclophosphamide. Each 
group received alternate-day predni so-
lone. The primary end point was the 
proportion of patients with complete or 
